Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS
Study data from Johns Hopkins University, Medical Department update knowledge of HIV/AIDS
August 20th, 2008
"Highly active antiretroviral therapy (HAART) can control HIV-1 replication(1,2), but suboptimal treatment allows for the evolution of resistance and rebound viremia(3-8). A comparative measure of antiviral activity under clinically relevant conditions would guide drug development and the selection of regimens that maximally suppress replication," researchers in the United States report. "Here we show that current measures of antiviral activity, including IC50 and inhibitory quotient, neglect a key dimension, the dose-response curve slope. Using infectivity assays with wide dynamic range, we show that this slope has noteworthy effects on antiviral activity. Slope values...
Source: Vaccine Weekly (2008-08-20)
|
